Denali Therapeutics Inc (NASDAQ:DNLI) Receives $26.33 Consensus Target Price from Brokerages

Denali Therapeutics Inc (NASDAQ:DNLI) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $25.50.

A number of brokerages have issued reports on DNLI. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. HC Wainwright set a $28.00 price objective on Denali Therapeutics and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Zacks Investment Research cut Phoenix New Media from a “hold” rating to a “sell” rating in a research note on Tuesday.

In other news, insider Carole Ho sold 17,500 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $22.85, for a total value of $399,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ryan J. Watts sold 18,334 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $24.20, for a total value of $443,682.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 130,000 shares of company stock valued at $2,715,736. 21.20% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp raised its position in Denali Therapeutics by 2.4% during the fourth quarter. Northern Trust Corp now owns 613,964 shares of the company’s stock valued at $12,685,000 after purchasing an additional 14,105 shares during the period. New York State Common Retirement Fund raised its position in Denali Therapeutics by 114.9% during the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock valued at $924,000 after purchasing an additional 23,900 shares during the period. Legal & General Group Plc raised its position in Denali Therapeutics by 16.3% during the fourth quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock valued at $179,000 after purchasing an additional 1,212 shares during the period. Bank of New York Mellon Corp raised its position in Denali Therapeutics by 11.7% during the fourth quarter. Bank of New York Mellon Corp now owns 227,505 shares of the company’s stock valued at $4,700,000 after purchasing an additional 23,809 shares during the period. Finally, Ibex Investors LLC purchased a new stake in Denali Therapeutics during the first quarter valued at approximately $209,000. 71.70% of the stock is owned by institutional investors.

Shares of NASDAQ DNLI traded up $0.52 during mid-day trading on Friday, hitting $21.06. 8,978 shares of the stock traded hands, compared to its average volume of 277,366. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.55 and a current ratio of 11.55. Denali Therapeutics has a 52 week low of $12.32 and a 52 week high of $28.86. The company has a market capitalization of $1.97 billion, a P/E ratio of -53.54 and a beta of 2.12. The stock has a fifty day moving average of $20.15.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative net margin of 38.84% and a negative return on equity of 10.23%. The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $12.88 million. Analysts forecast that Denali Therapeutics will post -1.54 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: What Factors Can Affect Return on Equity?

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.